Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19678581

Indexing Status
Subject indexing assigned by NLM

MeSH
Adjuvants, Immunologic /administration & dosage /economics; Cost-Benefit Analysis; Drug Costs; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta /administration & dosage /economics; Markov Chains; Multiple Sclerosis, Relapsing-Remitting /drug therapy /economics; Peptides /administration & dosage /economics; Quality-Adjusted Life Years; Serbia

AccessionNumber
22009103325

Date bibliographic record published
10/02/2010